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MaBACKGROUND T cells and macrophages are implicated in the pathogenesis of aortic aneurysm (AA) and atheroscle-
rosis. We recently demonstrated that a vaccine using an apoB-100–related peptide p210 reduces atherosclerosis with
favorable modulation of CD8þ T cells in apolipoprotein E–deﬁcient (apoE/) mice.
OBJECTIVES This study hypothesized that a p210 vaccine could reduce AA formation in the angiotensin II
(Ang II)–induced AA model.
METHODS Male apoE/ mice were immunized with p210 vaccine and implanted with an Ang II–releasing pump for
4 weeks. Flow cytometry assessed T cell activation and phenotype. Interleukin-6 (IL-6) and monocyte chemotactic
protein 1 (MCP-1) expression were assessed using reverse transcription polymerase chain reaction. We used ex vivo aortic
explants to test monocyte adhesion and in vitro cocultures to evaluate CD8þ T cell function.
RESULTS The p210 vaccine activated CD8þ T cells and reduced AA formation and mortality due to AA rupture, which
was attenuated by CD8þ T cell depletion. Vaccination decreased expression of IL-6 and MCP-1 and reduced macro-
phage inﬁltration in the aorta. Cytotoxic T-lymphocyte assay showed that CD8þ T cells from p210-immunized mice had
higher lytic activity against Ang II–stimulated macrophages. The p210 vaccine decreased splenic Th17 cells, and in vitro
coculture of CD4þ and CD8þ T cells showed that CD8þ T cells from p210-immunized mice inhibited the polarization of
CD4þ T cells into Th17 cells. IL-17A/ mice infused with a higher dose of Ang II did not develop AA rupture.
CONCLUSIONS A p210 vaccine protected against Ang II–induced AA formation and mortality by reducing macrophage
inﬁltration in the aorta and decreasing Th17 cell polarization. Our ﬁndings provide a potentially novel immunomodu-
lating approach against AA. (J Am Coll Cardiol 2015;65:546–56) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
AA = aortic aneurysm
Ang II = angiotensin II
apo = apolipoprotein
apoE/ = apolipoprotein
E–deﬁcient
cBSA = cationic bovine
serum albumin
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547Macrophages, in particular, play a pivotal role in
angiotensin II (Ang II)–induced AA formation and
rupture (5–8). The interaction of T cells with
antigen-presenting cells, such as macrophages and
dendritic cells, thus provide the prime condition for
immune activation (9). Clonal expansion of T cells
in human AA (10,11) strongly suggests antigen-
speciﬁc immune activation, supporting the view
that T cells are an important component of this com-
plex disease.SEE PAGE 557
IL = interleukin
MCP = monocyte chemotactic
protein
PBS = phosphate-buffered
saline
We have demonstrated that immunization with an
apolipoprotein B-100 (apoB-100)–related peptide,
p210, reduces atherosclerosis in hyperlipidemic
apolipoprotein E–deﬁcient (apoE/) mice (12). The
antiatherosclerotic effect of p210 vaccine was due to
immunomodulation of CD8þ T cells (12) independent
of antibody production (12,13). Given the commonal-
ity of the inﬂammatory pathways and the involve-
ment of T cells, modulation of T cell function also may
be a potential strategy to temper AA formation.
Hence, we tested the hypothesis that immunization
with p210 vaccine could reduce aortic inﬂammation
and AA formation in a murine model of AA induced by
Ang II infusion.
METHODS
A full description of the methods is available in the
Online Appendix. In brief, male apoE/ mice were
immunized with p210 vaccine, and as described pre-
viously (12,13), 100 mg of the peptide (Euro-Diagnostica
AB, Malmö, Sweden) was conjugated to cationic
bovine serum albumin (cBSA) as carrier and freshly
prepared prior to each immunization with alum as
adjuvant in a 1:1 volume ratio. The mice were sub-
cutaneously immunized with p210/cBSA/alum con-
jugate in the dorsal area at 7 weeks of age, followed
by boosters at 10 and 12 weeks of age. Mice receiving
cBSA/alum or phosphate-buffered saline (PBS) served
as control groups.
At 10 weeks of age, an osmotic pump (Alzet model
2004, DURECT Corporation, Cupertino, California)
was subcutaneously implanted in the back for a
continuous infusion of Ang II (Sigma-Aldrich, St.
Louis, Missouri) at a dose of 1,000 ng/kg/min for
4 weeks to induce AA (6–8,14). Online Figure IA
depicts the protocol and experimental groups.
Anti-CD8 antibody treatment depleted CD8þ T cells
in a subgroup of p210-vaccinated mice. For this CD8þ
T cell depletion group, p210-immunized mice were
intraperitoneally injected with 150 mg of anti-CD8
antibody (eBioscience, San Diego, California), clone53-6.7 (15), or isotype-matched rat immuno-
globulin G (IgG) as control (Sigma-Aldrich)
3 days before ﬁrst immunization and then
twice weekly thereafter. The depletion was
assessed by ﬂow cytometry (Online Figure IB).
C57BL/6 wild-type (WT) mice and inter-
leukin (IL)-17A/ mice were subcutaneously
implanted with an osmotic pump at 10 weeks
of age to continuously infuse a higher dose of
Ang II (2,500 ng/kg/min) for 4 weeks to induce
AA (14,16). Flow cytometry assessed T cell
activation and phenotype (Online Figure IB),
and IL-6 and monocyte chemotactic protein
1 (MCP-1) expression were assessed using
reverse transcription polymerase chain reac-
tion. Ex vivo aortic explants were used to test mono-
cyte adhesion, and in vitro cocultures were performed
to evaluate CD8þ T cell function.
Digital images of the whole aorta were acquired
at euthanasia after removal of loose adipose tissue,
and maximal aortic diameter was measured with Im-
age Pro software (Media Cybernetics, Rockville,
Maryland). AA was deﬁned as aortic size 1.5  greater
than aortas from saline-infused mice as previously
reported (17). Aneurysm severity was classiﬁed with
modiﬁcation (6) as the following: type 0: normal
aorta; type I: dilated with no thrombus; type II:
remodeled aorta that frequently contains thrombus;
type III: a pronounced bulbous form of type II with
thrombus; type IV: multiple aneurysms containing
thrombus; and type V: aortic dissection or rupture
with death.
The Institutional Animal Care and Use Committee
of Cedars-Sinai Medical Center approved all animal
experiments.
RESULTS
IMMUNE RESPONSES. Subcutaneous infusion of Ang
II for 4 weeks produced AAs in naïve apoE/ mice as
previously described (5). To assess the humoral im-
mune response to the vaccine, circulating levels of
p210 IgG antibody generated by immunization were
tested. The p210 IgG response was similar between
the p210 vaccine and cBSA group, but higher when
compared with PBS control mice (Online Figure IC), a
ﬁnding similar to previous reports using the p210
vaccine (12,13).
To explore the cellular immune responses to p210
vaccine, spleen cells were stained for cell surface and
activation markers. As shown in Figure 1, CD8þIL-12þ
T cell and CD8þCD25þIL-12þ T cell populations
signiﬁcantly increased in p210-immunized mice,
indicating that p210 immunization activated CD8þ
FIGURE 1 Cellular Immune Responses to p210 Vaccine Immunization in Splenocytes
Isotype
CD
8
CD4
CD8
CD8
PBS cBSA p210
6.1% 4.4% 11.4%
IL
-1
2
15 50 25
20
15
10
5
0
25
0
10
5
0
PBS cBSA p210 PBS cBSA p210 PBS cBSA p210
∗ ∗ ∗ ∗
∗ ∗
%
 o
f C
D8
 G
at
ed
 C
el
ls
%
 o
f C
D8
+C
D2
5+
 G
at
ed
 C
el
ls
%
 o
f C
D1
1c
+C
D8
6+
 G
at
ed
 C
el
ls
CD11c+CD86+IFN-γ+CD8+CD25+IL-12+CD8+IL-12+
A
B C D
(A) Representative scatter grams display gating strategy for ﬂow cytometric analysis of splenocytes on the basis of isotype control. p210 vaccine signif-
icantly increased (B) CD8þIL-12þ T cell and (C) CD8þCD25þIL-12þ T cell populations. Number of mice: PBS ¼ 3, cBSA ¼ 5, p210 ¼ 5. (D) p210 vaccine
signiﬁcantly increased CD11cþCD86þIFNgþ dendritic cell population. Number of mice: PBS ¼ 7, cBSA ¼ 8, p210 ¼ 8. *p < 0.05 versus p210. cBSA ¼ cationic
bovine serum albumin; IFN ¼ interferon; IL ¼ interleukin; PBS ¼ phosphate-buffered saline.
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548T cells. CD11cþCD86þ interferon (IFN)gþ dendritic
cells also signiﬁcantly increased in p210-immunized
mice. No signiﬁcant differences were observed in
CD4þIL-12þ T cells or in IL-10þ and IFNgþ cells in both
CD4þ and CD8þT cells (data not shown).
P210 VACCINE EFFECTS. Subcutaneous infusion of
Ang II for 4 weeks resulted in 84.8% of mice in the
cBSA group and 81.1% in the PBS group developing
AAs. In contrast, only 54.8% of p210-immunized mice
developed AAs, reﬂecting a signiﬁcant 30% decrease
in the incidence of aneurysm formation (p < 0.05 vs.
both control groups) without differences in circu-
lating cholesterol levels or body weight (Online
Table). This reduced incidence of aneurysm forma-
tion also was accompanied by a signiﬁcant reduction
in severity, as indicated by a left-shifted distribution
of severity score (Figure 2A) and reduced maximum
aortic diameter in p210-immunized mice compared
with the control groups (Figure 2B). Mortality due to
AA rupture as determined by necropsy wassigniﬁcantly reduced with p210 vaccine compared
with the cBSA and PBS groups at the 14-, 21-, and 28-
day time points (Figure 2C). Selective CD8þ T cell
activation after vaccination, as demonstrated in
Figure 1, suggests a crucial role for CD8þ T cells in the
vaccine’s effects (12). Thus, p210 vaccinated mice
treated with a CD8þ T cell-depleting monoclonal
antibody (CD8 Ab) experienced a signiﬁcantly blunted
protective effect of the p210 vaccine against mortality
due to AA rupture compared with isotype control mice
at the 14- and 21-day time points (Figure 2D).
One pivotal mechanism underlying aneurysm for-
mation and aortic dissection/rupture in this model is
the increased expression of IL-6 and MCP-1 with
recruitment of macrophages into the aortic wall,
resulting in an IL-6/MCP-1 ampliﬁcation loop (14). To
assess if p210 vaccine interrupted the IL-6/MCP-1
ampliﬁcation loop, we examined gene expression in
the aorta and found that p210 vaccine signiﬁcantly
reduced IL-6, MCP-1, and the MCP-1 receptor che-
mokine receptor 2 expression (Figures 3A to 3C).
FIGURE 2 Effects of p210 Vaccine on AA Formation, Severity, and Mortality Due to Rupture
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(A) Aneurysm severity and (B)maximum aortic diameter are reduced in p210-vaccinated mice. *p < 0.05 versus p210. (C) Kaplan-Meier survival
curve shows survival rates at 28 days were 64.9% for the PBS, 69.6% for the cBSA, and 90.5% for the p210 groups. Number of mice: PBS¼ 37,
cBSA ¼ 46, p210 ¼ 42. †p < 0.05 versus p210; ‡p # 0.01 versus p210. (D) CD8 depletion with monoclonal antibody (CD8 Ab) blunted
the improved survival rate of p210-vaccinated mice compared with control immunoglobulin G (isotype). Number of mice: CD8 Ab ¼ 14,
isotype ¼ 13. *p < 0.05; §p ¼ 0.1. AA ¼ aortic aneurysm; other abbreviations as in Figure 1.
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549To determine if reduced IL-6/MCP-1 expression
would affect macrophage inﬁltration in the aortic
wall, frozen suprarenal aortic aneurysmal sections
were stained with anti–monocyte/macrophage-2
antibody (Figures 3D to 3F). Quantitative analysis
demonstrated that immunization with p210 vac-
cine signiﬁcantly reduced macrophage inﬁltration
in the adventitia of the suprarenal aortic wall
(Figure 3G).
To further explore the mechanism of reduced
macrophage inﬁltration in the aortic wall in p210-
immunized mice, we assessed monocyte function
using an ex vivo monocyte adhesion assay (18).
Adhesion to the aorta was signiﬁcantly attenuated in
monocytes derived from p210-immunized mice
(Figures 4A and 4B). The monocytic expression of
MCP-1 was also decreased in p210-immunized mice(Figure 4C). The results indicated that p210 immuni-
zation altered monocyte/macrophage function.
We then tested whether aortic gelatinolytic activity
was affected by p210 immunization given the role of
matrix degradation in vascular remodeling. Using
in situ zymography with DQ-gelatin ﬂuorescence
(Life Technologies, Thermo Fisher Scientiﬁc Inc.,
Waltham, Massachusetts), we determined that gelat-
inolytic activity in aortas from p210-immunized mice
was signiﬁcantly reduced compared with the control
groups (Online Figure II).
CD8D T CELL ACTIVITY. We have previously de-
monstrated that CD8þ T cells mediate the protective
effect of p210 immunization in part by increased
cytolytic activity against dendritic cells (12). Given
that macrophages are antigen-presenting cells and
FIGURE 3 Effects of p210 Vaccine on IL-6, MCP-1, and CCR2 Expression and Macrophage Inﬁltration in Aorta
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The messenger ribonucleic acid (mRNA) expression of (A) IL-6, (B) MCP-1, and (C) CCR2 in aortas as analyzed by quantitative real-time reverse
transcription polymerase chain reaction. Number of mice: (A) PBS ¼ 11, cBSA ¼ 14, p210 ¼ 10; (B) PBS ¼ 7, cBSA ¼ 10, p210 ¼ 8; and (C)
PBS ¼ 12, cBSA ¼ 13, p210 ¼ 10. (D to F) Representative pictures of inﬁltration of macrophage in aneurysmal aortic wall assessed by monocyte/
macrophage (MOMA)-2 immunohistochemical staining (reddish-brown stain) for mice in the (D) PBS, (E) cBSA, and (F) p210 groups.
10  magniﬁcation; bar ¼ 0.01 mm; the box highlights the area magniﬁed at 20  (inset in each photo). (G) Quantitative analysis of MOMA-2
staining in adventitia of aorta. All of the analyzed sections were from suprarenal aorta. Number of mice: PBS ¼ 7, cBSA ¼ 9, p210 ¼ 8.
*p < 0.05 versus p210; †p < 0.01 versus p210. AU ¼ arbitrary units; CCR2 ¼ chemokine receptor 2; MCP ¼ monocyte chemotactic protein;
other abbreviations as in Figure 1.
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FIGURE 4 p210 Vaccine Effects on Monocytes and Macrophages
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(A) Representative pictures of adhesion of carboxyﬂuorescein diacetate succinimidyl ester-labeled monocytes (green) to aortas in ex vivo
adhesion assay. (B) Quantitative analysis of adhered monocytes demonstrates signiﬁcant attenuation of adhesion to the aorta in p210-treated
mice. Number of mice: PBS ¼ 8, cBSA ¼ 6, p210 ¼ 6. (C) MCP-1 mRNA expression in monocytes is also decreased in p210-immunized mice.
Monocytes were pooled from 3 to 4 mice in each group to obtain sufﬁcient material for isolation. Each assay was performed twice. (D) Cytotoxic
activity against Ang II–stimulated macrophages by CD8þ T cells from the different groups was signiﬁcantly higher in p210-immunized mice
compared with the PBS or cBSA groups (PBS ¼ 8.6  2.1%, cBSA ¼ 14.9  2.6%, p210 ¼ 23.2  2.9% speciﬁc lysis). CD8þ T cell/macrophage
ratio was 10:1. n ¼ 8 per group. *p < 0.05 versus p210; †p < 0.01 versus p210. CTL ¼ cytotoxic T lymphocyte; other abbreviations as in
Figures 1 and 3.
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551can also present p210 peptide sequences as an
antigen, we hypothesized that CD8þ T cells from
p210-immunized mice could have similar cytolytic
activity against macrophages (12). Cytotoxic T lym-
phocyte assay was performed using Ang II–stimulated
peritoneal macrophages as target cells and CD8þ T
cells as effector cells. The cytolytic activity against
Ang II–stimulated macrophages was signiﬁcantly
higher in CD8þ T cells from p210-immunized mice
when compared with CD8þ T cells from the PBS or
cBSA groups (Figure 4D).
IL-6 has recently been shown to mediate the local
CD4þIL-17Aþ T cell (Th17 cells) accumulation inaorta in this Ang II infusion model (16,19). Thus, we
hypothesized that p210 immunization would modu-
late Th17 cell polarization. Th17 cells were assessed
in spleens, given that systemic administration of
Ang II in mice results in systemic inﬂammatory re-
sponses. There were signiﬁcantly lower Th17 cells in
p210-immunized mice compared with control mice
(Figures 5A and 5B). To examine how the p210 vaccine
decreased the population of Th17 cells in the spleen,
in vitro coculture experiments were performed. It has
been shown that CD8þ T cells mediate CD4þ T cell
polarization into Th17 cells (20). Thus, we tested if
Ang II–induced Th17 polarization of CD4þ T cells was
FIGURE 5 p210 Vaccine Effects on Th17 Polarization
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(A) Representative scatter gram of gating strategy for Th17 cells. Gating and quadrant analysis was on the basis of isotype control. (B) p210
vaccine signiﬁcantly decreased splenic CD4þIL-17Aþ T cell (Th17) population. Number of mice: PBS ¼ 8, cBSA ¼ 6, p210 ¼ 6. (C) In vitro
costimulation of T cells with Ang II and CD3/CD28 antibody induces Th17 polarization only in the presence of CD8þ T cells. n ¼ 3 each. (D) CD8þ
T cells from p210-immunized mice signiﬁcantly inhibited the polarization of CD4þ T cells into Th17 cells induced by Ang II and CD3/CD28
antibody (PBS ¼ 0.40  0.03%, cBSA ¼ 0.32  0.01%, p210 ¼ 0.23  0.03%, no CD8 ¼ 0.19  0.04%). n ¼ 3 each. *p < 0.05 versus p210;
†p < 0.01 versus p210; ‡p < 0.05; ||p < 0.05 versus no CD8; §p < 0.01 versus no CD8. SSC ¼ side scatter plot of cells; other abbreviations as in
Figure 1.
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552also mediated by CD8þ T cells. As shown in Figure 5C,
the presence of CD8þ T cells was required for CD4þ T
cells to differentiate into Th17 cells stimulated with
Ang II and CD3/CD28 antibodies. We then explored
whether p210 immunization affected the ability of
CD8þ T cells to mediate Th17 polarization induced by
Ang II and TCR stimulation. Figure 5D shows that
CD8þ T cells from p210-immunized mice inhibited the
polarization of CD4þ T cells into Th17 cells compared
with control mice.
ROLE OF IL-17A. To explore the direct involvement of
Th17 cells in AA formation, IL-17A (/) and C57BL/6J
WT mice were implanted with an osmotic pump that
released high doses of Ang II. The mean maximum
aortic diameter of IL-17A/ mice was signiﬁcantlysmaller compared with WT mice (Figure 6A). More
importantly, none of the IL-17A/mice died, whereas
about 30% of WT mice died due to AA rupture, as
determined at necropsy (Figure 6B), conﬁrming
IL-17A’s crucial role in Ang II–induced aortic expan-
sion and AA rupture (16).
DISCUSSION
This study’s major ﬁnding is that an apoB-100–related
peptide p210 vaccine protected against AA formation,
severity, and death due to rupture in an Ang
II–induced murine AA model (Central Illustration).
The relevance of low-density lipoprotein (LDL) and
its protein component apoB-100 in aneurysm
FIGURE 6 Role of IL-17A in AA Formation and Rupture
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(A)Maximum aortic diameter in control wild-type (WT) mice (1.14  0.05 mm) was signiﬁcantly increased by Ang II infusion (1.45  0.09 mm).
Ang II–infused IL-17A/ mice had signiﬁcantly smaller maximum aortic diameter (1.18  0.03 mm) compared with Ang II–infused WT mice.
Number of mice: WT control ¼ 5, WT þ Ang II ¼ 11, IL-17A/ þ Ang II ¼ 13. *p < 0.05; †p < 0.01. (B) Kaplan-Meier survival curve shows a
signiﬁcant difference in survival rates: WT ¼ 73%, IL-17A/ ¼ 100%. Number of mice: WT ¼ 15, IL-17A/ ¼ 13. ‡p < 0.05 versus IL-17A/.
Abbreviations as in Figures 1 and 2.
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553formation is supported by several clinical studies,
including a report of perturbations in the plasma
concentration of apoB-100 in abdominal AA patients
(21). More recently, genome-wide association study
analysis for risk proﬁles of lipid factors found signif-
icant association for genetic scores of LDL and
abdominal AA (22), and an association between a
variant of the LDL receptor with abdominal AA was
also reported (23).
Mechanistically, we demonstrated that p210
immunization: 1) down-regulated IL-6 and MCP-1
expression in the aorta; 2) reduced macrophage
inﬁltration in the aortic wall; 3) decreased Th17 cell
polarization; and 4) activated CD8þ T cells, with
higher cytotoxic activity against Ang II–stimulated
macrophages. Additionally, we conﬁrmed the crucial
role of CD8þ T cells in the vaccine protection against
mortality due to AA rupture and the physiological role
of IL-17A in Ang II–induced AA formation.
THE IL-6/MCP-1 LOOP. One of the most important
factors that mediates aneurysm formation in the Ang
II–induced AA model is increased macrophage inﬁl-
tration in the aorta (5,8,24). The presence of CD4þ and
CD8þ T cells in human aneurysmal aortic wall has also
been reported previously (2,3,25). Ang II is a potent
inducer of vascular inﬂammation and IL-6 produc-
tion. IL-6 regulates monocyte-to-macrophage differ-
entiation and activation in the aorta along withMCP-1 production. The IL-6/MCP-1 ampliﬁcation loop
accelerates macrophage inﬁltration in the aneurysmal
aorta and plays an important role in AA formation and
dissection (14). Reduced aortic IL-6 and MCP-1
expression and decreased macrophage inﬁltration in
the aortic wall are consistent with the antianeurysmal
effect of p210 vaccine.
The ex vivo monocyte adhesion assay further
showed that adhesion activity was signiﬁcantly atten-
uated in monocytes derived from p210-immunized
mice, partly due to reduced monocytic expression
of MCP-1. Thus, the p210 vaccine decreased aortic
macrophage inﬁltration through down-regulation of
the aortic IL-6/MCP-1 ampliﬁcation loop and reduced
adhesion activity of monocytes to the aorta.
THE IL-6 AND TH17 AXIS. The crucial role of IL-6 in
aneurysm formation and rupture was further elabo-
rated by the recent report of IL-6-mediated polariza-
tion of Th17 cells via signal transducer and activator
of transcription-3 signaling (16). IL-17A deﬁciency
protected against early development of aortic
dissection and dilation by decreasing aortic MCP-1
expression and macrophage recruitment (16). IL-6 is
known to induce the differentiation of CD4þ T cells to
Th17 cells; IL-17A also induces IL-6 expression, sug-
gesting an IL-17A–triggered feed-forward loop of IL-6
signaling (26,27).
In our study, p210-immunized mice had a signiﬁ-
cantly lower Th17 cell population compared with
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Apolipoprotein B (ApoB)-100–related peptide p210 vaccine modulates activity of
CD8þ T cells to protect against aortic aneurysm (AA) formation, severity, and death
due to rupture by down-regulating the interleukin (IL)-6/monocyte chemotactic
protein (MCP)-1 loop and reducing macrophage inﬁltration in an angiotensin II
(Ang II)–induced murine AA model.
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554control mice. Interestingly, a recent study has sug-
gested that CD8þ T cells mediate Th17 polarization by
activated CD4þ T cells (20). In agreement with this
report, we show that CD8þ T cells were required for
CD4þ T cells to polarize into Th17 cells after T cell
receptor stimulation and Ang II treatment. Further-
more, CD8þ T cells from p210-immunized mice
signiﬁcantly inhibited the polarization of CD4þ T cells
to Th17 cells in vitro. Thus, we provide a novel
pathway of immune signaling mediated by CD8þ
T cells that results in Th17 activation in Ang II–
induced AA. The detrimental effect of IL-17A in
AA reported by Ju et al. (16) was conﬁrmed in our
study by the profound difference in maximum aortic
diameter and reduced mortality in IL-17A/ mice
compared with WT mice.
CD8D T CELLS IN ANEURYSM. Our previous report
indicated that the atheroprotective effect of p210vaccine was likely mediated by increased cytotoxic
activity of CD8þ T cells against a small population of
dendritic cells (12). We, therefore, tested if CD8þ
T cells from p210-immunized mice would likewise
have enhanced cytotoxic activity against macro-
phages, which could result in reduced presence in
the aneurysmal wall. The results of the cytotoxic
T lymphocyte assay suggested that CD8þ T cells from
p210-immunized mice could interact directly with
macrophages inﬁltrating the aortic wall, also consis-
tent with the reduced aortic macrophage inﬁltration
in p210-immunized mice.
The altered function of CD8þ T cells in p210-
vaccinated mice, resulting in attenuated aneurysmal
response to Ang II, complements a previously re-
ported pivotal role of CD8þ T cells in another model of
aneurysm formation. In that report, absence of CD8þ
T cells resulted in signiﬁcantly attenuated aneurysm
development in the elastase perfusion model (28).
The authors suggested a hierarchical order of T cell
responses to inﬂammatory signals during aneurysm
formation, with a proposed early function by CD8þ
T cells followed by directed polarization or lineage
commitment of CD4þ T cells. Indeed, this sequence is
compatible with immune responses in other disease
models, attributed in part to the ability of CD8þ
T cells to rapidly respond to immune challenges
(29,30). The CD8þ T cell-mediated Th17 polarization
and its modulation by the p210 vaccine is also
consistent with this view. Attenuation of the protec-
tion by p210 vaccine against aneurysm rupture and
death in the CD8þ T cell depletion experiment afﬁrms
the crucial role of CD8þ T cells in mediating the vac-
cine’s protective effects.
The clinical relevance of our ﬁndings is demon-
strated by evidence of T cell clonality in human AA
(10,11). Clonality indicates speciﬁcity to antigenic
immune epitopes. Whether immune reactivity in
human AA is toward antigens derived from patho-
genic organisms, self-proteins, or a combination of
both through molecular mimicry remains to be
elucidated (9).
STUDY LIMITATIONS. We tested the efﬁcacy of p210
immunization for antianeurysm effects in the Ang
II–infusion model only. This is an accelerated model
of aneurysm formation, unlike the chronic process
with clinical manifestation in late adulthood in
humans. Progress in the understanding of aortic
aneurysm in humans is particularly challenging
because the etiology remains vague, but there is ev-
idence supporting the relevance of the Ang II model
in human aneurysm formation (31). Completion of
clinical trials using modulators of the renin-
angiotensin system should provide more deﬁnitive
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Immunologically-mediated inﬂammatory signaling involving
CD8þ T cell responses is an important mechanism in the patho-
genesis of AA formation, growth, and rupture.
TRANSLATIONAL OUTLOOK: Strategies speciﬁcally target-
ing immunological signaling pathways may lead to a new para-
digm of vaccine therapy to alleviate aortic aneurysmal disease.
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555answers. Hence, our results must be interpreted with
caution for potential clinical implications given that
the study utilizes the classic vaccination approach,
where the possible onset of a disease is reduced or its
detrimental effects mitigated. Our results serve the
purpose of a positive “proof-of-concept” study for
further investigation of the vaccination strategy,
especially when combined with the previously re-
ported beneﬁcial atheroprotective effect of p210 im-
munization (12). Thus, we view the vaccine through
the prism of cardiovascular disease attenuation, in its
broadest practical application.
CONCLUSIONS
This study conﬁrms the role of inﬂammatory
signaling in Ang II–induced AA and extends the
previous studies by conﬁrming the novel role of
CD8þ T cells in AA. This is evidenced by the pivotal
role of CD8þ T cells in p210 vaccine protection
against Ang II–induced AA formation, severity, and
mortality due to AA rupture through inhibition of
the IL-6/MCP-1 ampliﬁcation loop, with reduced
macrophage inﬁltration and Th17 cell polarization.Our ﬁndings may provide a potentially new immu-
nomodulating approach against aortic aneurysmal
disease.
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